Zevra Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $25,881 | $20,401 | $12,043 | $3,695 |
Gross Profit | 13,502 | 19,056 | 10,677 | 1,392 |
EBITDA | -71,039 | 1,701 | -16,526 | -29,296 |
EBIT | -72,690 | 52 | -18,174 | -30,913 |
Net Income | 74,707 | -3,099 | -35,739 | -33,225 |
Net Change In Cash | 25,881 | 20,401 | 12,043 | 3,695 |
Free Cash Flow | -3,814 | -8,321 | -16,250 | -18,141 |
Cash | 47,712 | 37,340 | 33,785 | 54,039 |
Basic Shares | 56,324 | 54,095 | 53,670 | 47,808 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $23,612 | $27,461 | $10,161 | $28,650 |
Gross Profit | 16,195 | 24,516 | 9,939 | 26,591 |
EBITDA | -76,400 | -43,542 | -25,526 | -7,888 |
EBIT | -82,789 | -44,548 | -26,470 | -8,145 |
Net Income | -105,511 | -46,049 | -26,772 | -8,555 |
Net Change In Cash | 23,612 | 27,461 | 10,161 | 28,650 |
Free Cash Flow | -69,665 | -33,831 | -18,810 | 10,337 |
Cash | 33,785 | 43,049 | 65,466 | 112,346 |
Basic Shares | 46,251 | 35,452 | 34,488 | 29,766 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | -$0.06 |
2025-03-31 | -$0.06 |
2024-12-31 | -$0.69 |
